Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 5/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225582 | 0.83 | TSHR (0.66) | TP53TSHREPHX1KMT2AMEN1 | |
| SCHEMBL31412811 | 0.83 | TSHR (0.66) | TP53TSHREPHX1KMT2AMEN1 | |
| SCHEMBL9162199 | 0.81 | TP53 (0.44) | TP53TSHRMMEACACBEPHX1 | |
| SCHEMBL31412800 | 0.81 | TP53 (0.63) | TP53TSHRACACBKMT2AMEN1 | |
| SCHEMBL5872655 | 0.81 | TSHR (0.63) | TP53TSHRACACBKMT2AMEN1 | |
| SCHEMBL227153 | 0.81 | TP53 (0.63) | TP53TSHRACACBKMT2AMEN1 | |
| SCHEMBL17550074 | 0.79 | TSHR (0.61) | TP53TSHRNPC1RAB9A | |
| SCHEMBL204959 | 0.79 | TP53 (0.61) | TP53TSHRKMT2A | |
| SCHEMBL1148 | 0.79 | TSHR (0.61) | TP53TSHRACACBEPHX1KMT2A | |
| SCHEMBL13889195 | 0.79 | TP53 (0.61) | TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111201212-B | Synthesis method of feloxicib and intermediate thereof | 四川青木制药有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-107686471-B | Synthesis method of feloxicib and intermediate thereof | 成都苑东生物制药股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-111201212-A | Synthesis method of feloxicib and intermediate thereof | 四川青木制药有限公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| CN-106659715-A | substituted aminotriazoles and methods of use thereof | 药物发现研究所 | 2017-05-10 | — | — | CN | disclosed |
| EP-3082805-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | The Institute For Drug Delivery (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
| EP-0009865-A1 | Process for the stereoselective synthesis of the E isomer of aryl alkyl oximes | RHONE-POULENC INC. (US) | 1980-04-16 | — | — | EP | disclosed |
| US-4158015-A | Process for the stereoselective synthesis of the E isomer of aryl alkyl oximes | MOBIL OIL CORPORATION (US) | 1979-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | TP53 356/4885TSHR 1742/4885MME 3194/4885 |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | TP53 3200/4885TSHR 3816/4885MME 70/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | TP53 356/4885TSHR 1742/4885MME 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.